SCHEMBL5322124

SCHEMBL5322124

Cc1cc(Cl)ccc1Cn1nc(CC(=O)O)c2ccc(C(F)(F)F)cc21

nearest known ligand 0.54

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 10/20 0.54
PTGDR2 Q9Y5Y4 4/20 0.46
SLC22A12 Q96S37 5/20 0.44
KMO O15229 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5317956 0.90 AKR1B1 (0.56) AKR1B1PTGDR2SLC22A12
SCHEMBL5318259 0.89 KMO (0.46) AKR1B1PTGDR2SLC22A12KMO
SCHEMBL5317839 0.89 AKR1B1 (0.55) AKR1B1PTGDR2SLC22A12
SCHEMBL5316058 0.88 KMO (0.44) AKR1B1PTGDR2SLC22A12KMO
SCHEMBL4097771 0.86 CYP1A2 (0.54) AKR1B1PTGDR2SLC22A12KMO
SCHEMBL5270492 0.86 AKR1B1 (0.39) AKR1B1PTGDR2SLC22A12KMO
SCHEMBL5318197 0.85 PTGDR2 (0.49) AKR1B1PTGDR2SLC22A12KMO
SCHEMBL5317400 0.85 SLC22A12 (0.52) AKR1B1PTGDR2SLC22A12KMO
SCHEMBL5318544 0.84 AKR1B1 (0.38) AKR1B1PTGDR2SLC22A12KMO
SCHEMBL5317649 0.83 AKR1B1 (0.38) AKR1B1PTGDR2SLC22A12KMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2502624-A1 Lonidamine analogues and their use in male contraception and cancer treatment THE UNIVERSITY OF KANSAS (US) 2012-09-26 EP claimed
EP-1786424-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT The University of Kansas (US) 2007-05-23 EP claimed
WO-2006023704-A2 LONIDAMINE ANALOGUES AND THEIR USE IN MALE CONTRACEPTION AND CANCER TREATMENT UNIVERSITY OF KANSAS (US) 2006-03-02 WO claimed
EP-2502624-A1 Lonidamine analogues and their use in male contraception and cancer treatment THE UNIVERSITY OF KANSAS (US) 2012-09-26 EP disclosed